Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease

Next Previous
Trial Profile

An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 6012 (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Coronary artery disease
  • Focus Adverse reactions
  • Sponsors AlphaCore Pharma

Most Recent Events

  • 09 Oct 2012 Results have been reported in an AlphaCore Pharma media release.
  • 09 Oct 2012 Primary safety endpoints have been met, according to an AlphaCore media release.
  • 09 Oct 2012 Status changed from recruiting to completed, based on an AlphaCore Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top